A Clinical Practice Guideline Summary for Pharmacological Management of Adults with Major Depressive Disorder in Malaysia

被引:0
|
作者
Abousheishaa, Aya Ahmed [1 ]
Sue-Yin, Low [2 ]
Khin, Kok Chee [3 ]
Sulaiman, Ahmad Hatim [1 ]
Huri, Hasniza Zaman [4 ]
Guan, Ng Chong [1 ]
机构
[1] Univ Malaya, Dept Psychol Med, Fac Med, Kuala Lumpur, Malaysia
[2] HELP Univ, Fac Behav Sci, Dept Psychol, Kuala Lumpur, Malaysia
[3] Univ Malaya, Dept Pharm, Med Ctr, Kuala Lumpur, Malaysia
[4] Univ Malaya, Fac Pharm, Kuala Lumpur, Malaysia
关键词
Major depressive disorder; clinical practice guidelines; evidence-based practice; RECOMMENDATIONS; ADAPTATION; ADHERENCE; MOOD;
D O I
10.9734/JPRI/2021/v33i45B32821
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Clinical Practice Guidelines (CPGs) are systematically developed statements to assist practitioners and patients with appropriate health care for specific clinical circumstances. However, evidence suggests that the uptake of these recommendations in routine care is still limited, particularly in resource-constrained countries. Objectives: This article aimed to (1) identify current CPGs for the pharmacological management of MDD that address and are compatible with the needs of Malaysian psychiatrists (2) collate and summarise these CPG recommendations to produce a more culturally sensitive and end-user friendly guideline summary. Materials and Methods: A multidisciplinary steering group followed an adapted development approach that included; (1) searching for guidelines on the pharmacological management of adults with depression, (2) screening them for relevant recommendations, (3) critical appraising these guidelines, and (4) extracting the required information. A panel of experts then reviewed the developed guideline summary. Results: Six potentially relevant guidelines for the pharmacological management of depression in adults were identified. The developed summary included a decision algorithm to guide the selection of antidepressant therapy based on clinical factors, potential drug-drug interaction, tolerability, and cost of the medications. The review panel considered the summary recommendations easy to use and had the potential for uptake by busy psychiatrists. Conclusion: A CPG summary for the pharmacological management of depression was developed that focuses on evidence-based, contextually relevant recommendations that are feasible for implementation within the local healthcare settings in Malaysia. Practical Implications: The developed guideline summary has the potential to enhance the implementation of evidence-based practice in the management of Major Depressive Disorder within the Malaysian context.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 50 条
  • [21] The Current Situation on Major Depressive Disorder in China:Research on Mechanisms and Clinical Practice
    Zhenghua Hou
    Wenhao Jiang
    Yingying Yin
    Zhijun Zhang
    Yonggui Yuan
    NeuroscienceBulletin, 2016, 32 (04) : 389 - 397
  • [22] The Current Situation on Major Depressive Disorder in China: Research on Mechanisms and Clinical Practice
    Zhenghua Hou
    Wenhao Jiang
    Yingying Yin
    Zhijun Zhang
    Yonggui Yuan
    Neuroscience Bulletin, 2016, 32 : 389 - 397
  • [23] Vilazodone: A Review in Major Depressive Disorder in Adults
    Paul L. McCormack
    Drugs, 2015, 75 : 1915 - 1923
  • [24] Escitalopram for treatment of major depressive disorder in adults
    Llorca, PM
    Brousse, G
    Schwan, R
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (04): : 490 - 501
  • [25] Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
    Cao, Bing
    Zhu, Judy
    Zuckerman, Hannah
    Rosenblat, Joshua D.
    Brietzke, Elisa
    Pan, Zihang
    Subramanieapillai, Mehala
    Park, Caroline
    Lee, Yena
    McIntyre, Roger S.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 92 : 109 - 117
  • [26] Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
    Chauhan, Mohit
    Parry, Rebecca
    Bobo, William, V
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 1175 - 1193
  • [27] Management of opioid use disorder: 2024 update to the national clinical practice guideline
    Yakovenko, Igor
    Mukaneza, Yvette
    Germe, Katuschia
    Belliveau, Jacob
    Fraleigh, Ross
    Bach, Paxton
    Poulin, Ginette
    Selby, Peter
    Goyer, Marie-Eve
    Brothers, Thomas D.
    Rehm, Jurgen
    Hodgins, David C.
    Stewart, Sherry H.
    Wood, Evan
    Bruneau, Julie
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (38) : E1280 - E1290
  • [28] New agents and perspectives in the pharmacological treatment of major depressive disorder
    Sanches, Marsal
    Quevedo, Joao
    Soares, Jair C.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2021, 106
  • [29] Clinical practice guideline for the integrated management of major trauma by the Italian National Institute of Health: process and methods
    Fauci, Alice Josephine
    Coclite, Daniela
    Napoletano, Antonello
    D'Angelo, Daniela
    Biffi, Annalisa
    Castellini, Greta
    Gianola, Silvia
    Iacorossi, Laura
    Latina, Roberto
    Porcu, Gloria
    Salomone, Katia
    Chiara, Osvaldo
    Iannone, Primiano
    ANNALI DELL ISTITUTO SUPERIORE DI SANITA, 2021, 57 (04): : 343 - 351
  • [30] Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer
    Okamura, Masako
    Akizuki, Nobuya
    Nakano, Tomohito
    Shimizu, Ken
    Ito, Tatsuhiko
    Akechi, Tatsuo
    Uchitomi, Yosuke
    PSYCHO-ONCOLOGY, 2008, 17 (02) : 154 - 160